# Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

> **NCT00347412** · PHASE3 · COMPLETED · sponsor: **Cellectar Biosciences, Inc.** · enrollment: 903 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** NOV-002
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00347412
- **Lead sponsor:** Cellectar Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-01
- **Final completion:** 2010-02
- **Target enrollment:** 903 (ACTUAL)
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00347412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00347412, "Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00347412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*